| 胸腔积液CEA、CA125检测对非小细胞肺癌预后判断的价值 |
| 投稿时间：2011-01-03 修订日期：2011-01-26 点此下载全文 |
| 引用本文：郑志鸿.胸腔积液CEA、CA125检测对非小细胞肺癌预后判断的价值[J].医学研究杂志,2012,41(1):139-141 |
| DOI：
|
| 摘要点击次数: 1014 |
| 全文下载次数: 965 |
|
|
| 中文摘要:目的探讨胸腔积液中癌胚抗原（CEA）和癌抗原125（CA125）在恶性胸腔积液非小细胞肺癌（NSCLC）的预后价值。方法共有75例确诊恶性胸腔积液NSCLC患者被归纳入本研究，通过ELISA方法检测胸腔积液标本的CEA和CA125水平。结果NSCLC胸腔积液中CEA≥100ng/ml或CA125≥1000U/ml患者中位生存时间有所缩短，但都不能作为独立的预后因素（P>0.05）。而胸腔积液中CEA≥100ng/ml和CA125≥1000U/ml的患者中位生存时间有更显著缩短（4.0个月 vs 8.5个月，P<0.05）。结论NSCLC患者恶性胸腔积液中CEA和CA125同时升高可作为一个独立的预后因素，对指导晚期NSCLC个体化治疗有着重要意义。 |
| 中文关键词:非小细胞肺癌 肿瘤标志物 恶性胸腔积液 |
| |
| High Level of CEA and CA125 in Pleural Fluid Correlates with Poor Survival in NSCLC Patients with Malignant Effusions |
|
|
| Abstract:ObjectiveTo determine whether CEA and CA125, either alone or in combination, could be used to predict survival time of patients with malignant pleural effusion due to advanced non-small cell lung cancer (NSCLC). MethodsSeventy-five chemonaive patients with NSCLC malignant pleural effusion had been enrolled. Pleural fluid tumor markers were evaluated by enzyme-linked immuno sorbent assay. ResultsIn patients with malignant effusion, CEA or CA125 cannot remained as an independent predictor of poor outcome. However, the combination of CEA≥100ng/ml and CA125≥1000U/ml predicted a lower survival (4.0 vs 8.5 months，P<005). ConclusionThe combination of pleural fluid CEA and CA125 can remain as an independent predictor of poor outcome in NSCLC patient with malignant pleural effusion, which can provide individualized treatment strategy for advanced NSCLC patients. |
| keywords:Non-small cell lung cancer Tumor markers Malignant pleural effusion |
| 查看全文 查看/发表评论 下载PDF阅读器 |
